Iantrek announced it closed $23 million in Series B financing that will go toward initiating clinical trials of its MIGS devices, according to a press release.
The company unveiled its CycloPen, which targets the suprachoroidal outflow pathway, earlier this year. The first cases using the devices were performed earlier this month, according to the release.
“There remains a significant unmet clinical need to provide safe and effective micro-interventional tools for aqueous outflow management,” Iantrek CEO Sean Ianchulev, MD, said in the release. “We are grateful to have a